XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Values of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Assets and liabilities measured at fair value are summarized below:

 

    Total Fair Value     Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)    

Significant Other Observable Inputs

(Level 2)

    

Significant Unobservable Inputs

(Level 3)

  
Assets:                                
                                 
Recurring items as of December 31, 2020                                
Corporate debt securities, available for sale   $ –      $ –     $ –     $ –  
                                 
Non-recurring items as of December 31, 2020                                
In-process R&D (Note 5)   $ 13,366,234     $ –     $ –     $ 13,366,234  
                                 
Recurring items as of December 31, 2019                                
Corporate debt securities, available for sale   $ 7,985,886     $ –     $ 7,985,886     $ –  
                                 
Non-recurring items as of December 31, 2019                                
In-process R&D (Note 5)   $ 15,736,491     $ –     $ –     $ 15,736,491  
                                 
Liabilities:                                
                                 
Recurring items as of December 31, 2020                                
Earn-out milestone liability (Note 12)   $ 7,018,000     $ –     $ –     $ 7,017,000  
                                 
Recurring items as of December 31, 2019                                
Earn-out milestone liability (Note 12)   $ 5,717,709     $ –     $ –     $ 5,717,709